This article says as of May GSK and Vir were planning on manufacturing 2 million doses in a year, but trying to figure out ways to make more.
I mean who is this "we" you keep talking about? The USG - "we" - wrote a blank check. What else can be done by "us"?
It seems like you want it to be better. I'm sure GSK and Vir want to be able to make more too. There is essentially a time-bound profit opportunity here, in raw terms. I don't think the bottleneck is lack of funding or effort. It seems manufacturing monoclonal antibodies is an expensive and long process.Quote:
"I don't feel good that the competition got knocked out, frankly, because we're talking about lifesaving treatments," Scangos said. In the first year following the drug's authorization in May, Vir and GlaxoSmithKline had planned to manufacture 2 million treatments, but the companies are trying to find ways to increase manufacturing capacity.
The government moved to conserve sotrovimab when early analysis of omicron's mutations suggested the drug might hold up against the variant, Kessler said. A growing number of studies have bolstered confidence that it will still work. But the supply is limited, with about 50,000 total doses on hand an inventory expected to grow to about 350,000 by early January, according to Kessler. The U.S. government distributed 180,000 doses to states before the pause in late November. The distribution data does not report which doses have been used.
I mean who is this "we" you keep talking about? The USG - "we" - wrote a blank check. What else can be done by "us"?